The largest database of trusted experimental protocols

21 protocols using il 21

1

Isolation and Differentiation of Primary Human B Cells and Monocytes

Check if the same lab product or an alternative is used in the 5 most similar protocols
Primary human B cells and monocytes were isolated using the RosetteSep Human B Cell and monocyte Enrichment Cocktails (StemCell Technologies) as per the manufacturer's instructions from leukocyte cones provided by UK National Health Service Blood and Transplant. Isolated cells were cultured in RPMI-1640 supplemented with 10% FCS, 4 mM L-glutamine, 10 mM HEPES, 1% non-essential amino acid solution (Gibco), and 1% penicillin-streptomycin solution (Gibco) at 37°C, 5% CO2. B cells were also cultured in the presence of 1 mM sodium pyruvate (Gibco), 50 ng/ml IL4 (PeproTech), 25 ng/ml IL2 (PeproTech), 100 ng/ml BAFF (BioLegend), and 100 ng/ml IL21 (BioLegend). Monocytes were differentiated into moDCs by culturing with 50 ng/ml IL4 (PeproTech) and 100 ng/ml GM-CSF (Immunotools) at 1 × 106/cm2 in adherent culture for 6 days. Twenty-four h before use in T cell stimulation assays, moDCs were activated by addition of 1 μM prostaglandin E2 (Sigma-Aldrich), 50 ng/ml TNFα (PeproTech), 10 ng/ml IL1β (Bio-Techne), and 20 ng/ml IFNγ (Bio-Techne). Differentiation was confirmed by assessing expression of CD11c and CD86 (see “Flow cytometry”).
+ Open protocol
+ Expand
2

B Cell Culture and Activation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Human B cells (preenriched, enriched, and depleted) from six donors were cultured in Iscoves modified Dulbeccos medium (IMDM; Gibco, Fisher Scientific) supplemented with 10% HI FBS (Gibco), 2:1,000 MycoZap (Lonza, Alpharetta, GA), 10,000 U/ml interleukin-2 (IL-2; Gibco), and 100 μg/ml IL-21 (BioLegend). Additionally, the medium was treated with antibody-cross-linked CD40L (Miltenyi Biotec), according to the manufacturer’s protocols, or 1 ng/ml CD40L homotrimer (BioLegend) in plates coated with 10 μg/ml anti-His antibody (BioLegend) or 3T3-msCD40L feeder cells obtained through the NIH AIDS Reagent Program (catalog no. 12535 3T3-msCD40L; Division of AIDS, NIAID, NIH, from Mark Connors, as described in reference 22 (link)). Although three different CD40L delivery methods were used, no statistical difference in IgGtot production was found between the three (not shown). B cells were plated with 3,000 to 5,000 cells/ml and incubated at 37°C in 5% CO2 for up to 12 days, after which the supernatant was collected and stored at –80°C for downstream analysis.
+ Open protocol
+ Expand
3

Cytokine-Induced STAT Phosphorylation Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Forty-eight hours after transduction, cells were first reseeded in IL-2–free media for 4 h, then cultured in RPMI medium with 10% FBS and anti–CD8-biotin Ab (53–6.7; eBioscience) in the presence or absence of rIL-2 (50 U/ml) for 10 min to induce STAT5 phosphorylation. For STAT1 and STAT3 phosphorylation, cells were cultured in the presence or absence of IFN-α (5000 U/ml; 30 min; BioLegend) or IL-21 (200 ng/ml; 30 min; BioLegend), respectively, and anti–CD8-biotin was added for the last 10 min. Cells were then fixed in 2% paraformaldehyde (5 min) and fixation reagent (15 min) (FIX & PERM Cell Permeabilization Kit; Thermo Fisher Scientific) and made permeable with ice-cold methanol (15 min) and permeabilization medium (FIX & PERM Cell Permeabilization Kit; Thermo Fisher Scientific), then stained with anti-GFP Ab (Thermo Fisher Scientific), anti–p-STAT1-PE (A15158B), anti–p-STAT3-AF647 (13A3–1; all from BioLegend), anti–p-STAT5 allophycocyanin (SRBCZX), streptavidin-PE (all from eBioscience), and streptavidin-allophycocyanin (Invitrogen). Cells were analyzed with a CytoFLEX S (Beckman Coulter) Flow Cytometer.
+ Open protocol
+ Expand
4

Cytokine-Induced STAT Phosphorylation Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Forty-eight hours after transduction, cells were first reseeded in IL-2–free media for 4 h, then cultured in RPMI medium with 10% FBS and anti–CD8-biotin Ab (53–6.7; eBioscience) in the presence or absence of rIL-2 (50 U/ml) for 10 min to induce STAT5 phosphorylation. For STAT1 and STAT3 phosphorylation, cells were cultured in the presence or absence of IFN-α (5000 U/ml; 30 min; BioLegend) or IL-21 (200 ng/ml; 30 min; BioLegend), respectively, and anti–CD8-biotin was added for the last 10 min. Cells were then fixed in 2% paraformaldehyde (5 min) and fixation reagent (15 min) (FIX & PERM Cell Permeabilization Kit; Thermo Fisher Scientific) and made permeable with ice-cold methanol (15 min) and permeabilization medium (FIX & PERM Cell Permeabilization Kit; Thermo Fisher Scientific), then stained with anti-GFP Ab (Thermo Fisher Scientific), anti–p-STAT1-PE (A15158B), anti–p-STAT3-AF647 (13A3–1; all from BioLegend), anti–p-STAT5 allophycocyanin (SRBCZX), streptavidin-PE (all from eBioscience), and streptavidin-allophycocyanin (Invitrogen). Cells were analyzed with a CytoFLEX S (Beckman Coulter) Flow Cytometer.
+ Open protocol
+ Expand
5

Naive B cell activation and plasma cell differentiation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Naive B cells from healthy donors and BENTA patients were cultured in Iscove’s modified Dulbecco medium (IMDM) plus 10% fetal bovine serum supplemented with penicillin/streptomycin (Sigma). Purified B cells were plated at 1 × 106 cells/mL in 24-well flat-bottom plates (1 mL/well) or 96-well round bottom plates (0.2 mL/well). Cells were activated using (a) 100 ng/mL of dextran-conjugated anti-IgD antibodies (αIgD-DEX) (Fina Biosolutions), (b) SAC (Protein A from Staphylococcus aureus Cowan I) + 200 U/mL of rIL-2 (Peprotech), or (c) 10 µg/mL of Affinipure F(ab′2) fragment-specific goat anti-human IgM (Jackson Immunoresearch Laboratories) plus 1 µg/mL anti-CD40 Ab (AF632, R&D Biosystems) plus IL-21 (100 ng/mL, Biolegend) and IL-2 (20 U/mL, Biolegend). For (c), additional combinations of cytokines (Biolegend) IL-4 (100 ng/mL) + IL-13 (50 U/mL), or IL-10 (25 ng/mL) were concomitantly used to induce isotype-specific antibody responses. For long-lived plasma cell generation, IL-6 (10 ng/mL), IFN-α (100 U/mL), and IL-21 (100 ng/mL) along with Lipid Mixture 1, chemically defined (Sigma, 1:500 dilution) and MEM amino acids solution (Sigma, 1:100 dilution) were added on day 6 to cells that were previously stimulated with α-IgM Ab/α-CD40 Ab/IL-21/IL-2. Culture media was changed every 4 days.
+ Open protocol
+ Expand
6

B cell activation and gene expression

Check if the same lab product or an alternative is used in the 5 most similar protocols
B cells were placed on PLB containing anti-human Igκ or anti- rat Igκ antibodies and incubated at 37°C with 5% CO2 and 75% humidity for 1 h. RPMI-10 culture media containing anti-CD40 antibody (2ug/mL, R&D systems), IL-4 (40ng/mL, R&D systems), and IL-21 (2ug/mL Biolegend), or RPMI-10 culture media alone was added to the cells, cells were incubated at 37°C for an additional 2 h and harvested. Cells were lysed, RNA was reverse transcribed, and cDNA was used to run TaqMan Gene Expression Assays using TaqMan Gene Expression Cells-to-CT kit (Thermo Fisher) on CFX connect Real-Time PCR Detection System (Bio Rad, check model name again). TaqMan Gene Expression Assays detecting IRF-4 (Hs00180031_m1, Thermo Fisher) and ACTB (Hs1060665_g1, Thermo Fisher) were used to measure levels of mRNA and ACTB was used for normalization. Data were analyzed by Prism software (GraphPad).
+ Open protocol
+ Expand
7

Evaluating iTreg Stability Under Stress

Check if the same lab product or an alternative is used in the 5 most similar protocols
For evaluation of iTreg stability, cells were (1) re‐stimulated without iTreg differentiation components and (2) challenged with Th17‐polarising cytokines. For (1), cells were re‐stimulated using 500 U mL−1 of IL‐2 and a 1:1 expander beads without addition of TGF‐β, ATRA and rapamycin, for 7 days at 1 × 106 cells mL−1 then rested with 500 U mL−1 of IL‐2 for 3 days at 2 × 106 cells mL−1, after an initial 7‐day stimulation and 3‐day rest. On day 3 of rest, cells were used for flow cytometric analysis and in vitro suppression assay. For (2), cells were challenged for 3 days with Th17‐polarising cytokines, IL‐1β, IL‐6, IL‐21 and IL‐23 (10 ng mL−1 for all, Biolegend, San Diego, CA, USA), in the presence of 25 U mL−1 of IL‐2 and a 1:10 expander beads at 1 × 106 cells mL‐1, after an initial 7‐day stimulation and 3‐day rest. Cells were stimulated with 25 U mL−1 of IL‐2 and a 1:10 expander beads at 1 × 106 cells mL−1 as unchallenged controls. On day 3 of challenge, cells were washed three times with PBS (+2% FCS). After washing, expander beads were magnetically removed. Cells were used for flow cytometric analysis, cytokine production assays and reverse transcription quantitative polymerase chain reaction.
+ Open protocol
+ Expand
8

Cytokine Stimulation of CD8+ T Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
CD8+ T cell lines or ex vivo single cell suspensions from the epithelial compartment (obtained as described in Supplemental Methods) were stimulated with human recombinant IL15 (Biolegend), IL21 (Biolegend) or IL2 (NIH AIDS Reagent Program) at the indicated concentrations for 20 minutes for signaling experiments, western blot (WB) and flow cytometry, or 2 hours for RNA-sequencing (RNA-seq). BNZ-2, or a control peptide (CP), scrambled sequence of BNZ-2, was added at the indicated concentrations ten minutes prior to cytokine stimulation.
Additional details are in the Supplementary materials and methods section.
+ Open protocol
+ Expand
9

Comprehensive Immune Cell Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols
Antibodies: CD279 (PD1) (Clone PD1.3 Beckman Coulter), CD45RA (Clone ALB11 Beckman Coulter), CD185 (CXCR5) (Clone J252D4 Biolegend), CD4 (Clone 13B8.2 Beckman Coulter), CD20 (Clone B9E9 Beckman Coulter), CD19 (Clone J4.119 Beckman Coulter), CD38 (Clone HB-7 Biolegend), CD27 (Clone M-T271 Biolegend), IGD (Clone IA6-2 Biolegend), CD11c (Clone BU15 Beckman Coulter), CD14 (Clone RMO52 Beckman Coulter), CD16 (Clone 3G8 Beckman Coulter), CD24 (Clone ALB9 Beckman Coulter), CD45 (Clone J.33 Beckman Coulter), CD3 (Clone UCHT1 Beckman Coulter), CD8 (Clone B9.11 Beckman Coulter), CD56 (Clone N901 Beckman Coulter), CD57 (Clone NC1 Beckman Coulter), CD25 (Clone B1.49.9 Beckman Coulter), CD127 (Clone R34.34 Beckman Coulter), CD159a (NKG2A)(Clone S19004C Biolegend), CD337 (NKp30) (Clone P30-15 Biolegend), IFN-γ (Clone 45.15 Beckman Coulter), IL-21 (Clone 3A3-N2 Biolegend), IL-17 (Clone BL168 Beckman Coulter), granzyme (Clone QA16A02 Biolegend), perforin (Clone B-D48 Biolegend)
Flow Cytometer: Navios, Beckman Coulter
Cytometric Bead Array: RAISECARE; Analysis Software: Kaluza, LEGEND plex.
+ Open protocol
+ Expand
10

Quantifying IRF4 and IRF8 Expression

Check if the same lab product or an alternative is used in the 5 most similar protocols
To test IRF4 and IRF8 expression, 14,000 to 15,000 sorted B cells were incubated in complete RPMI at 37°C with 5% CO2 for 24 hours in chambers without any stimulations, or with BCR stimulation with either PLBs containing biotinylated goat F(ab′)2 anti-human λ + κ (SouthernBiotech) for membrane Ag engagement or 10 nM biotinylated goat F(ab′)2 anti-human λ + κ (SouthernBiotech) for soluble antigen engagement. The cells stimulated for BCR were supplemented with CpG (ODN2006) (1.25 μg/ml, Invivogen), IL-2 (50 ng/ml, BioLegend), IL-21 (100 ng/ml, BioLegend), IL-10 (250 ng/ml, BioLegend), and BAFF (100 ng/ml, R&D Systems). Following incubation, cells were lysed, and RNA was extracted using Lysis Solution from the Cells-to-CT 1-Step TaqMan Kit (Invitrogen) following the manufacturer’s protocol. Expression of IRF4 and IRF8 in the cell lysates was analyzed by reverse transcription and qRT-PCR.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!